StableEyes With Active Neurofeedback

Launched by JOHNS HOPKINS UNIVERSITY · Nov 11, 2022

Keywords

ClinConnect Summary

This clinical trial, called "StableEyes With Active Neurofeedback," is studying a new self-help tool designed to help people who experience motion sickness or have vestibular disorders. Essentially, it aims to guide users in gradually moving their heads more to reduce feelings of dizziness and improve balance, especially after certain medical procedures. The trial is currently looking for participants of various ages who are generally healthy or have been diagnosed with a specific type of tumor called unilateral vestibular schwannoma.

To join the study, participants need to be willing to follow the study rules and be healthy enough to comply with the rehabilitation program. However, individuals currently taking anti-nausea medication, those with certain neck or orthopedic issues that limit movement, or people who are legally blind cannot participate. If you decide to take part, you can expect to follow a set program that helps improve your balance and reduce motion sickness over time. This trial could be an important step in finding better ways to help people manage these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Provision of signed and dated informed consent form
• • 2. Stated willingness to comply with all study procedures and availability for the duration of the study
• • 3. In good general health as evidenced by medical history or diagnosed with unilateral vestibular schwannoma
• • 4. Willing to adhere to the SWAN and/or vestibular rehabilitation regimen
• Exclusion Criteria:
• • 1. Current use of anti-nausea medication
• • 2. Presence of cervical spine pathology that limits head motion to \< 30 degrees in the horizontal or vertical plane (i.e. degenerative disc disease, rheumatoid arthritis)
• • 3. Any orthopedic pathology that prevents walking or standing independently (i.e. recent surgery)
• • 4. Legal blindness (20/200 or worse visual acuity)
• • 5. Treatment using a motion sickness investigational drug or other motion sickness behavioral intervention within 30 days